IBRX - ImmunityBio Company Total Debt

ImmunityBio, Inc. (IBRX) is scaling Anktiva sales and penetrating new NK-cell niches. The total liabilities trend visualizes the financial burden, where 0.00 reflects the latest metric value. The operating model relies on full outsourcing of production and testing through external partners, while the R&D center aggressively advances IL-15 research to maximize the company's innovation potential.

NantKwest - IBRX Company Debts (period 07/04/2022 - 10/27/2026)

Financial and market metric breakdowns for ImmunityBio (IBRX)

- price and consensus price forecast:

Share Price NantKwest|IBRX - Analyst Consensus Forecast

- market capitalization data:

Market Valuation ImmunityBio Corp|IBRX - Total Company Value

- book capitalization data:

Net Asset Value per Share ImmunityBio|IBRX - Company Book Value|Market Value to Book Value Ratio immunitybio.com|IBRX - Aggregate Company Assets

- debt and liquidity data:

Debt to Capital ImmunityBio, Inc.|IBRX - Long-Term Debt to Capital|Short-Term Indebtedness to Equity ImmunityBio Inc|IBRX - Company Total Debt|Debts to Book Value ImmunityBio Corp

Fundamental company valuation:IBRX (NantKwest)

Developing innovative vaccines in immuno-oncology requires significant capital, making debt load control critical for the financial stability of ImmunityBio, Inc. (IBRX). This indicator aggregates obligations to creditors and bondholders, eliminating reporting time gaps for accurate solvency monitoring, which allows the investor to assess the balance between business scaling and debt burden via the total debt chart.

Main competitors